On June 25, 2025 Crinetics reported the management team for a R&D Day to discuss Company’s proprietary in-house discovery engine and proven development approach for differentiated endocrine therapies (Press release, Crinetics Pharmaceuticals, JUN 25, 2025, View Source [SID1234654117]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will highlight Crinetics’ early-stage pipeline strategy and data to deliver sustainable long-term growth, with a focus on:

NETs and beyond – NDC platform with CRN09682
TSH antagonist for Graves’ disease and thyroid eye disease (TED)
SST3 agonist for autosomal dominant polycystic kidney disease (ADPKD)
Date:
June 26, 2025
Time:
9:00 AM EDT
Virtual Meeting:
Note: You must register to be eligible to
participate in the meeting.